Amin Pharmaceutical Co (XTEH:AMIN1) Debt-to-EBITDA : 0.00 (As of . 20)

View and export this data going back to 1990. Start your Free Trial

What is Amin Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amin Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Amin Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Amin Pharmaceutical Co's annualized EBITDA for the quarter that ended in . 20 was IRR0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Amin Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

XTEH:AMIN1's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful Debt-to-EBITDA only.

Amin Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Amin Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amin Pharmaceutical Co Debt-to-EBITDA Chart

Amin Pharmaceutical Co Annual Data

Trend

Debt-to-EBITDA

Amin Pharmaceutical Co Semi-Annual Data

Debt-to-EBITDA

Competitive Comparison of Amin Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Amin Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amin Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amin Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amin Pharmaceutical Co's Debt-to-EBITDA falls into.

Amin Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amin Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(	+	)	/	N/A
	=	N/A

Amin Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Amin Pharmaceutical Co (XTEH:AMIN1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Amin Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amin Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Amin Pharmaceutical Co (XTEH:AMIN1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amin Pharmaceutical Co (XTEH:AMIN1) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Abolfazl Street, Bostan Heftam West Alley, No. 4, 2nd floor, Marzdaran, Tehran, IRN

Website

https://www.aminpharma.com

Amin Pharmaceutical Co is engaged in the manufacturing of pharmaceutical products, chemical drugs, herbal medicines, and nutritional supplements. It offers antimicrobials, cardiovascular, antidiabetic, cerebellar, gastrointestinal, antibiotic and antifungal, and hypoglycemic agents among others. It develops drugs in the form of plain and overlaid tablets, hard, and soft capsules, oral drops, syrups, and suspensions. Products offered by the company include Acarbose, Sitagliptin, Fampridine, Ofloxacin, Amiodarone, Ibuprofen, Zolpidem, Bilberry, Thyme, and others. Amin also exports its products to Afghanistan, Kazakhstan, Uzbekistan, and Iraq.

Amin Pharmaceutical Co (XTEH:AMIN1) Headlines

No Headlines